ReviewInternational journal of molecular sciences2020
Innate Immunity and Biological Therapies for the Treatment of Sjögren's Syndrome.
Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Treatment of Sjögren's Syndrome with Mesenchymal Stem Cells: A Systematic Review.International journal of molecular sciences · 2021Pooled it
- Pathological mechanisms of Sjögren's disease-related dry eye: from multiglandular dysfunction to ocular surface inflammation.International ophthalmology · 2026Review
- Pauci-Immune Crescentic Glomerulonephritis Associated With Primary Sjögren Syndrome: A Case Report.Cureus · 2026Article
- Therapeutic potential of TAM receptors in autoimmune diseases: insights from original studies.Oxford open immunology · 2026Review
- Diagnostic methods for managing dry eyes.World journal of methodology · 2025Article
- Real-World Assessment of Systemic Disease Activity in Seropositive and Seronegative Patients with Sjögren's Disease and Association with Patient-Reported Outcomes.Rheumatology and therapy · 2025Article
- Tissue-Resident Memory T Cells in Rheumatoid Immune Diseases: Pathogenic Mechanisms and Therapeutic Strategies.Biomedicines · 2025Review
- Elucidating Regulatory Mechanisms of Genes Involved in Pathobiology of Sjögren's Disease: Immunostimulation Using a Cell Culture Model.International journal of molecular sciences · 2025Article
- The multifaceted roles of exosomes in corneal biology: elucidation of underlying mechanisms and therapeutic applications.Molecular biology reports · 2025Review
- Route of Application and Dose Evaluation of Dental Pulp Stem Cells for the Treatment of Sialadenitis Caused by Sjögren's Syndrome: A Preclinical Study.Biomedicines · 2025Article
- Salivary gland macrophages in health and disease: heterogeneity, niche crosstalk, and therapeutic avenues.Frontiers in immunology · 2025Review
- Engineered cell therapies for autoimmune diseases: evaluating CAR-T and CAR-M progress and prospects.Frontiers in immunology · 2025Review
- Cell therapy in Sjögren's syndrome: opportunities and challenges.Expert reviews in molecular medicine · 2024Review
- Nanomedicines for Dry Eye Syndrome: Targeting Oxidative Stress with Modern Nanomaterial Strategies.Molecules (Basel, Switzerland) · 2024Review
- Research progress of T cell autophagy in autoimmune diseases.Frontiers in immunology · 2024Review
- Macrophages in guided bone regeneration: potential roles and future directions.Frontiers in immunology · 2024Review
- TNF is a critical cytokine in age-related dry eye disease.The ocular surface · 2023Article
- Review
- Article
- The Role of Regulatory T Cells in the Onset and Progression of Primary Sjögren's Syndrome.Cells · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Sjögren's syndrome (SS) is a systemic autoimmune disorder affecting approximately 3% of the population in the United States. This disease has a female predilection and affects exocrine glands, including lacrimal and salivary glands. Dry eyes and dry mouths are the most common symptoms due to the loss of salivary and lacrimal gland function. Symptoms become more severe in secondary SS, where SS is present along with other autoimmune diseases like systemic lupus erythematosus, systemic sclerosis, or rheumatoid arthritis. It is known that aberrant activation of immune cells plays an important role in disease progression, however, the mechanism for these pathological changes in the immune system remains largely unknown. This review highlights the role of different immune cells in disease development, therapeutic treatments, and future strategies that are available to target various immune cells to cure the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.